Laura Donker Kaat1, Lieke H Meeter2, Wan Zheng Chiu2, Shami Melhem2, Agnita J W Boon2, Kaj Blennow3, Henrik Zetterberg4, John C van Swieten5. 1. Department of Neurology, Erasmus Medical Center Rotterdam, The Netherlands; Department of Clinical Genetics, Leiden University Medical Center, The Netherlands. Electronic address: l.donkerkaat@erasmusmc.nl. 2. Department of Neurology, Erasmus Medical Center Rotterdam, The Netherlands. 3. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. 4. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, United Kingdom; UK Dementia Research Institute at UCL, London, United Kingdom. 5. Department of Neurology, Erasmus Medical Center Rotterdam, The Netherlands; Department of Clinical Genetics, VU Medical Center Amsterdam, The Netherlands.
Abstract
INTRODUCTION: Neurofilament light chain (NfL) is a promising biomarker in neurodegenerative diseases. Elevated NfL levels in CSF and blood have been observed in a growing number of neurodegenerative disorders, including frontotemporal dementia and Alzheimer's disease. We studied serum NfL levels in patients with progressive supranuclear palsy (PSP) in relation to disease severity and survival. METHODS: Serum NfL levels were determined cross-sectionally in a retrospective cohort of 131 patients with PSP and 95 healthy controls. Detailed clinical examination was performed and disease severity was assessed by several rating scales. RESULTS: We found that serum NfL levels in PSP were twice as high as those in controls, and that NfL levels correlated with worse functional, motor and cognitive functioning. During follow-up, 119 PSP patients had died, and higher NfL levels were associated with a shorter survival. CONCLUSION: This study provides evidence that serum NfL is a relevant and promising biomarker in PSP for disease severity, and may be used as a prognostic tool to predict survival in clinical practice.
INTRODUCTION: Neurofilament light chain (NfL) is a promising biomarker in neurodegenerative diseases. Elevated NfL levels in CSF and blood have been observed in a growing number of neurodegenerative disorders, including frontotemporal dementia and Alzheimer's disease. We studied serum NfL levels in patients with progressive supranuclear palsy (PSP) in relation to disease severity and survival. METHODS: Serum NfL levels were determined cross-sectionally in a retrospective cohort of 131 patients with PSP and 95 healthy controls. Detailed clinical examination was performed and disease severity was assessed by several rating scales. RESULTS: We found that serum NfL levels in PSP were twice as high as those in controls, and that NfL levels correlated with worse functional, motor and cognitive functioning. During follow-up, 119 PSPpatients had died, and higher NfL levels were associated with a shorter survival. CONCLUSION: This study provides evidence that serum NfL is a relevant and promising biomarker in PSP for disease severity, and may be used as a prognostic tool to predict survival in clinical practice.
Authors: Michael A Sugarman; Henrik Zetterberg; Kaj Blennow; Yorghos Tripodis; Ann C McKee; Thor D Stein; Brett Martin; Joseph N Palmisano; Eric G Steinberg; Irene Simkin; Andrew E Budson; Ronald Killiany; Maureen K O'Connor; Rhoda Au; Wendy Wei Qiao Qiu; Lee E Goldstein; Neil W Kowall; Jesse Mez; Robert A Stern; Michael L Alosco Journal: Neurobiol Aging Date: 2020-05-29 Impact factor: 4.673
Authors: Arie R Gafson; Nicolas R Barthélemy; Pascale Bomont; Roxana O Carare; Heather D Durham; Jean-Pierre Julien; Jens Kuhle; David Leppert; Ralph A Nixon; Roy O Weller; Henrik Zetterberg; Paul M Matthews Journal: Brain Date: 2020-07-01 Impact factor: 13.501
Authors: Maria Stamelou; Gesine Respondek; Nikolaos Giagkou; Jennifer L Whitwell; Gabor G Kovacs; Günter U Höglinger Journal: Nat Rev Neurol Date: 2021-08-23 Impact factor: 42.937
Authors: Sara Gil-Perotin; Jessica Castillo-Villalba; Laura Cubas-Nuñez; Raquel Gasque; David Hervas; Josep Gomez-Mateu; Carmen Alcala; Francisco Perez-Miralles; Francisco Gascon; Jose Andres Dominguez; Bonaventura Casanova Journal: Front Neurol Date: 2019-09-23 Impact factor: 4.003
Authors: Antoine Leuzy; Niklas Mattsson-Carlgren; Sebastian Palmqvist; Shorena Janelidze; Jeffrey L Dage; Oskar Hansson Journal: EMBO Mol Med Date: 2021-12-03 Impact factor: 12.137
Authors: Melissa M Budelier; Yingxin He; Nicolas R Barthelemy; Hong Jiang; Yan Li; Ethan Park; Rachel L Henson; Suzanne E Schindler; David M Holtzman; Randall J Bateman Journal: Brain Commun Date: 2022-02-22
Authors: Claudia Duran-Aniotz; Paulina Orellana; Tomas Leon Rodriguez; Fernando Henriquez; Victoria Cabello; María F Aguirre-Pinto; Tamara Escobedo; Leonel T Takada; Stefanie D Pina-Escudero; Oscar Lopez; Jennifer S Yokoyama; Agustin Ibanez; Mario A Parra; Andrea Slachevsky Journal: Front Neurol Date: 2021-06-24 Impact factor: 4.003